Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc and its finance subsidiary, Perrigo Finance plc, on December 2, 2014. The filing reports the closing of a material definitive agreement involving the issuance of senior notes to fund the proposed acquisition of Omega Pharma Invest NV.
Key Financial Metrics and Debt Issuance
The company announced the closing of a $1.6 billion senior notes offering. The specific tranches are as follows:
- 2021 Notes: $500 million aggregate principal amount at 3.50% interest per annum.
- 2024 Notes: $700 million aggregate principal amount at 3.90% interest per annum.
- 2044 Notes: $400 million aggregate principal amount at 4.90% interest per annum.
Interest payments are scheduled to commence semiannually on June 15, 2015. The notes are fully and unconditionally guaranteed by Perrigo Company plc on a senior unsecured basis. The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period.
Material Changes and Use of Proceeds
The primary material change is the increase in long-term debt obligations. The net proceeds from this offering, combined with proceeds from an ordinary share offering closed on November 26, 2014, and other financing sources, are intended to:
- Fund the cash consideration for the acquisition of Omega Pharma Invest NV.
- Repay or refinance certain indebtedness of the Company and/or Omega Pharma.
If the acquisition is not consummated, the net proceeds will be used to redeem the notes at 101% of the aggregate principal amount plus accrued interest.
Outlook, Risks, and Covenants
The indenture includes covenants restricting the company's ability to incur secured indebtedness, enter into sale and leaseback transactions, or consolidate/transfer substantially all assets. The notes are subject to a "make-whole" optional redemption feature and a change of control trigger requiring a repurchase offer at 101% of principal plus accrued interest.
Management highlights risks associated with the successful completion of the Omega Pharma transaction, product liability claims, market acceptance of products, and changes in tax laws. The filing includes standard forward-looking statement disclaimers regarding future financial performance.
Investor Verification Checklist
- Verify the final closing status of the Omega Pharma Invest NV acquisition.
- Confirm the total debt load post-issuance and the specific allocation of proceeds between the acquisition and debt refinancing.
- Review the full text of the Base Indenture and First Supplemental Indenture (Exhibits 4.1 and 4.2) for detailed covenant restrictions.
- Monitor the company's liquidity position to ensure compliance with interest payment obligations starting June 15, 2015.